One man’s meat is another man’s poison: metabolic and biomedical implications of autism and ReAttach
A particular medication can be very helpful and well tolerated by one person but unhelpful and very harmful for another. Some people with autism benefit dramatically from drugs known as SSRIs (selective serotonin re-uptake inhibitors) that are commonly used for treating depression (provided the dose is correct).
For others, especially those with more severe problems, the results can be disastrous.
The ReAttach intervention reduces psychological distress which has metabolic and biomedical implications too. How can choice of medication support the improved stress regulation?
Paul Shattock OBE is a British autism researcher and scientific consultant to the charity Education and Services for People with Autism, of which he is also the founder. He was formerly the director of the Autism Research Unit at the University of Sunderland. He is well known for his disputed research into dietary therapy and autism, having claimed that autistic children may have a “leaky gut” which allows certain peptides to enter the bloodstream, and claimed that they excrete unusually high levels thereof. As a result of this speculation, he has promoted the use of a gluten-free, casein-free diet to ameliorate the symptoms of autism, a theory he developed along with Kalle Reichelt. In addition, he has claimed that a protein found in milk may play a role in the aetiology of autism. He is also the former president of the World Autism Organization.
In 2002, Paul Shattock conducted a survey and claimed that this survey had identified a unique subset of autistic children who may be uniquely susceptible to the MMR vaccine. These children were identified by the fact that they tended to suffer from bowel problems, had an abnormal gait and were friendlier than other autistic children. In addition, this survey concluded that one in ten parents of autistic children attributed their child’s autism to this vaccine, and that these children had much higher levels of urinary indolyl-3-acryloylglycine.
Chairman of ESPA (Education and Services for People with Autism)
Dr. Paul Shattock, a pharmacist and parent of an autistic son, was Honorary Director of the Autism Research Unit (ARU), University of Sunderland, UK now called ESPA Research. He is Chairman of ESPA (Education and Services for People with Autism) which provides teaching and residential services for young adults with autism and President-Elect of the World Autism Organisation (WAO) having previously been secretary for Autisme-Europe. His research interests include rights and models of service provision for people with autism, biomedical and environmental factors implicated in autism, and the use and abuse of medication for autism.
Dr. Paul Shattock has published in peer-refereed journals, such as Autism, the Journal of Child Neurology, Biomedical Chromatography and the Journal of Pharmacy and Pharmacology.
In 1998 Mr Shattock was made an Officer of the Order of the British Empire (OBE) for his more than 30 years of services to the autism community.